Full Text Journal Articles from
Abstract 17267662


Find full text journal articles

Novel compounds with antiproliferative activity against imatinib-resistant cell lines.

PMID: 17267662 (view PubMed database entry)
DOI: 10.1158/1535-7163.mct-04-0307 (read at publisher's website )

Enrica I Lerma, Viet-Anh Nguyen, Tao Wang, Alex Tipping, Junia V Melo, Donald Kufe, David J Austin, Albert Deisseroth,

Chronic myelogenous leukemia is caused by the Bcr-Abl hybrid gene that encodes the p210Bcr-Abl chimeric oncoprotein. Although it reduces the total body burden of leukemia cells, the use of imatinib mesylate as a single agent may be accompanied by the evolution of resistance due mainly to the acquisition of point mutations. Imatinib has been combined with drugs that inhibit both the active and the inactive states of the p210Bcr-Abl kinase. These combinations have reduced but not completely eliminated the rate at which point mutations are acquired in the p210Bcr-Abl kinase. Thus, it is important to identify additional new inhibitors of the p210Bcr-Abl kinase. One possible method to prevent evolution of resistance is to simultaneously use multiple kinase inhibitors each with a different mechanism of action. To identify such a new class of inhibitors that could suppress the growth of chronic myelogenous leukemia cells and prevent the evolution of cells that are resistant to imatinib, we screened two low-complexity libraries of compounds based on planar and linear scaffolds. These libraries were screened using a cell-based assay for molecules that suppress p210Bcr-Abl-dependent cell growth. The application of this method resulted in the isolation of two new classes of drugs, both of which inhibited imatinib-resistant cells in the low micromolar range. Some of these drugs were potent inhibitors not only of Abl tyrosine kinase but also of the Src, Lyn, and Fyn tyrosine kinases.

Mol. Cancer Ther. (Molecular cancer therapeutics)
[2007, 6(2):655-666]

Cited: 3 times

AltMetric Statistics


0.4254 s